RxDoctor Payments Data

Chad Hogan, MD

Family Medicine · Grapevine, TXNPI 1235187279

Payments from drug & device makers

$1,823in general payments, 2019–2025

Across 73 payments — averaging $24.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$256
  • Lilly USA, LLC$253
  • Bayer$194
  • Astellas Pharma US Inc$187
  • E.r. Squibb & Sons, L.L.C.$125
  • Pfizer$121
  • plus $687 from 16 others

What the payments were for

  • Food & beverage$1,823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,823 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$112,044
Medicare patients
432
Services billed
1,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin109$159,315
EliquisApixaban93$117,550
TrulicityDulaglutide53$77,827
RybelsusSemaglutide43$72,131
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$68,556
MounjaroTirzepatide35$44,427
XareltoRivaroxaban29$44,010
OzempicSemaglutide32$43,964
JanuviaSitagliptin Phosphate15$24,446
LinzessLinaclotide20$19,801
Janumet XrSitagliptin Phos/Metformin Hcl11$16,632
MyrbetriqMirabegron17$13,550
JanumetSitagliptin Phos/Metformin Hcl14$11,932
Repatha SureclickEvolocumab15$9,058
Rosuvastatin Calcium646$8,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$253$122,25488 claims
PfizerEliquis$121$117,55093 claims
Novo NordiskRybelsus, Ozempic$115$116,09575 claims
GSKTrelegy Ellipta$256$68,55682 claims
MerckJanuvia, Janumet Xr, Janumet$31$53,01140 claims
Johnson & JohnsonXarelto$11$44,01029 claims
AbbVieLinzess, Synthroid$62$23,30885 claims
Astellas Pharma US IncMyrbetriq$187$13,55017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Grapevine

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →